Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: April 2014

VistaGen Therapeutics, Inc. (VSTA) Seeks to Bring Human Biology to Front End of Drug Development Process

In the late 1990s, VistaGen Therapeutics’ founders established the company to make their dreams a reality. The founders wanted to create human cell-based biological assay systems that provide reliable insight into the healing and harmful effects of new drug candidates … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

Merge Healthcare, Inc. (MRGE) iConnect® Network Signs 19 Contracts in Q1

Merge Healthcare, a provider of clinical systems for the healthcare industry, reports that its iConnect® Network interoperability solution received 19 new contracts in the first quarter of 2014. iConnect Network streamlines the exchange of clinical data to enable healthcare organizations … Continue reading

Posted in Small Cap News | Leave a comment

Methes Energies International Ltd. (MEIL) Processors Aligned with Push for Domestic, Clean Energy Source

Biodiesel is the only commercially available fuel that meets the Environmental Protection Agency’s (EPA) definition of “advanced biofuel.” The EPA reports that biodiesel reduces lifecycle greenhouse gases by 86 percent, hydrocarbon emissions by 67 percent, and generates a minimum of … Continue reading

Posted in Methes Energies International MEIL | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine

Today, VistaGen Therapeutics announced that it has received broader intellectual property protection for its stem cell technology platform. The United States Patent and Trademark Office recently issued a notice of allowance (NOA) for U.S. Patent Application 12/836,275, entitled “Cell populations … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

Continental Stock Transfer & Trust Company Offers End-To-End Support for Corporate Actions and Escrows

Besides the short-term and long-term variations in stock price, what investors most often remember are the formal corporate actions undertaken by a company. These actions are the major corporate plays that directly affect shareholders, and the timing and effectiveness with … Continue reading

Posted in Small Cap News | Leave a comment

Gogo, Inc. (GOGO) Multimedia Platform Enables In-Flight Entertainment, Communication, Internet Access

In 2008, Gogo made its debut as a provider of in-flight connectivity and wireless in-flight digital entertainment solutions. Six years later, more than 2,000 commercial and 6,500 business aircraft are equipped with the company’s exclusive products and services. Once the … Continue reading

Posted in Small Cap News | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Stem Cell Expertise Brings New Life to Discarded Drug Candidates

VistaGen Therapeutics is a San Francisco-based biotechnology company that focuses on human stem cell technology for the purposes of drug rescue, predictive toxicology, and drug metabolism screening. The company was founded in 1998 and has spent the last 16 years … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

Methes Energies International Ltd. (MEIL) Extensive Know-How Produces Client Success

Methes Energies is a biodiesel producer with a portfolio of products and services that aids companies in the biodiesel production industry. The company delivers a myriad of solutions for a wide range of challenges in the biodiesel industry. Methes Energies … Continue reading

Posted in Methes Energies International MEIL | Leave a comment

Busy IPO Market Making Up for Lost Time

Last week was a huge one for initial public offerings, as companies who had delayed the big move due to the country’s financial crisis now try to make up for lost time. Six of the companies on top of the … Continue reading

Posted in Small Cap News | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Commercial Drug Rescue Potential Underwritten by Stem Cell Bioassay’s Cardiac Drug Safety Benchmarking

VistaGen’s human pluripotent stem cell (hPSC) based approach to salvaging the massive outlays that are otherwise eaten when a once-promising drug candidate is dropped due to unexpected heart or liver toxicity complications (or preemptively preventing such losses), using their proprietary … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment